By asianet
The bone-derived skeletal growth factor (SGF), jointly developed by a research facility under the direction of leading biochemist, academician and researcher Zhao Yufen and the Anhui-based research center of one of the world’s health industry leaders People’s GuoTai Group (PGTG), broke through the formula stability bottleneck after unremitting efforts over the last three years and … Continued
By asianet
–Practical, innovative functionality seeks to alleviate eCOA burdens, reduce time-to-launch, and improve site, clinician, and patient experience. Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas such as oncology, central nervous system (CNS), and rare disease, today announced that as part of its single platform rollout, its electronic … Continued
By asianet
— Data unveiled at four industry conferences suggest a single ERA treatment may be more effective than combination therapies used today — Biomarker analysis demonstrates ERA’s regenerative impact on fibroblast proliferation, collagen VII production — eTurna(TM) lipid-based delivery platform proves groundbreakingly effective at reaching targeted tissue — Company to present updated data during January webinar … Continued
By asianet
Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization [https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=sustainability-report-2022](CRO/ CDMO), today announced the release of its Sustainability Report 2022, which has been developed as per the Global Reporting Initiative (GRI) standards. With the theme ‘Organising for Sustainability Success’ the Report describes the company’s efforts in progressively reducing the knowing-doing gap by … Continued
By asianet
— The Center at Rush University Will Be Directed By Dr. Elizabeth Berry-Kravis The Foundation for Angelman Syndrome Therapeutics (FAST) announced today a $5 million gift to establish the new clinical trial and translational research effort for rare neurodevelopmental disorders, a first-of-its-kind flagship center to be directed by Dr. Elizabeth Berry-Kravis. Named the Rush F.A.S.T. … Continued
By asianet
VEITH 2022 witnessed a surge of supporting clinical data for Sirolimus Coated Balloon in the treatment of Below-the-Knee (BTK) disease. Concept Medical Inc. [https://www.conceptmedical.com/] hosted a lunch symposium titled ‘Sirolimus Coated Balloon in PAD Treatment: Choice of The Future’ which explored the utility of Sirolimus Coated Balloon treatment in PAD. The session was chaired by … Continued
By asianet
– Best of SABCS(R) News Highlights coverage will provide daily expert video summaries along with original presentation slides of the most significant breast cancer trials for oncologists worldwide. Encore Medical Education [http://www.encoremeded.com/], a US-based medical education company will launch the 2022 edition of the Best of SABCS(R) News [https://bestofsabcsnews.com/] Highlights program from the 2022 San … Continued
By asianet
ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with Cosmo Bio. This is a non-exclusive license agreement granting Japan’s Cosmo Bio access to the ERS CRISPR/Cas9 patent portfolio. ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides access to the foundational CRISPR/Cas9 intellectual property. Over 100 patents … Continued
By asianet
– Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities – Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer’s Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco – For people with early … Continued
By asianet
• Elacestrant demonstrated longer progression-free survival (PFS) vs SOC endocrine therapy with medians up to 8.6 months, positively associated with the duration of prior treatment with CDK4/6 inhibitors • Elacestrant side effects were manageable and consistent with previously reported results • Results demonstrate that elacestrant may have the potential to become a new standard of … Continued